Lippman Evan sold 18,600 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $36.57 for −$680k on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP, Business Development
EVP, Business Development
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$680,291.28Shares × reported price
Shares traded
18,600Ordinary Shares
Price per share
$36.57Reported price. Read footnotes for ranges.
% of reported position traded
42.09%This security and ownership context
Holdings after
25,591Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 19, 2026, 4:00 PM ET2-day reporting delay
Accession
0001193125-26-356853Code S · Transaction 10931
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 44,191 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −15%1w ago −3.5%1d ago −1.9%
Returns since7d +1.2%30d +4.6%90d180d1y

Footnotes in full

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.